Roche Reveals Impact Of Multisource Biosimilar Competition
Avastin, Rituxan and Herceptin All Face Challengers
With biosimilars to Avastin on the way later this year in Europe, Roche will face competition to its three key biosimilar monoclonal antibodies in the US, EU and Japan. Management detailed to investors the company’s latest expectations.
You may also be interested in...
ChemoCentryx gets US approval of Tavneos for ANCA vasculitis, which it says may gradually ramp up to a blockbuster revenue opportunity. Current steroid-heavy standard of care has many drawbacks.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.